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Abstract
Background: To validate and recalibrate the CR- POSSUM model and compared its discriminatory capacity with
other European models such as POSSUM, P-POSSUM, AFC or IRCS to predict operative mortality in surgery for
colorectal cancer.
Methods: Prospective multicenter cohort study from 22 hospitals in Spain. We included patients undergoing
planned or urgent surgery for primary invasive colorectal cancers between June 2010 and December 2012
(N = 2749). Clinical data were gathered through medical chart review. We validated and recalibrated the predictive
models using logistic regression techniques. To calculate the discriminatory power of each model, we estimated
the areas under the curve - AUC (95% CI). We also assessed the calibration of the models by applying the
Hosmer-Lemeshow test.
Results: In-hospital mortality was 1.5% and 30-day mortality, 1.7%. In the validation process, the discriminatory
power of the CR-POSSUM for predicting in-hospital mortality was 73.6%. However, in the recalibration process, the
AUCs improved slightly: the CR-POSSUM reached 75.5% (95% CI: 67.3–83.7). The discriminatory power of the
CR-POSSUM for predicting 30-day mortality was 74.2% (95% CI: 67.1–81.2) after recalibration; among the other
models the POSSUM had the greatest discriminatory power, with an AUC of 77.0% (95% CI: 68.9–85.2).
The Hosmer-Lemeshow test showed good fit for all the recalibrated models.
Conclusion: The CR-POSSUM and the other models showed moderate capacity to discriminate the risk of operative
mortality in our context, where the actual operative mortality is low. Nevertheless the IRCS might better predict
in-hospital mortality, with fewer variables, while the CR-POSSUM could be slightly better for predicting 30-day
mortality.
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Background
Colorectal cancer is one of the most common cancers in
developed countries; in Europe alone, more than
340,000 people were diagnosed in 2012, and the inci-
dence is increasing in many countries [1]. The mainstay
of treatment is surgery, whether to resect the tumor
and/or its metastases or to alleviate symptoms of the
disease [2]. Surgery for colorectal cancer is highly
complex and involves significant risks that can lead to
unfavourable short-term outcomes. Operative mortality
(death after surgery before discharge from hospital or
within 30 days of surgery) is a quality indicator for
surgery, because of its relationship with preoperative
preparation and the quality of postoperative care, so it is
of the utmost importance to have explicit criteria to
know which patients require stricter surveillance.
Various authors have developed predictive models to
estimate the adjusted risk of death after a surgical
intervention; these models are based on a set of variables
(4–18, depending on the model) related to the patients
themselves, to their disease, and/or to the surgical
process. Some of these models can be applied to any
surgical patient, whereas others are specific to a particu-
lar type of surgery. The Physiological and Operative
Severity Score for the enUmeration of Mortality and
Morbidity [3] (POSSUM) and a modified version of this
score, the Portsmouth-POSSUM [4] (P-POSSUM), are
examples of models applicable to any surgical patient,
whereas the Colorectal POSSUM (CR-POSSUM) is a
version with fewer variables that is specific for patients
undergoing colorectal surgery [5].
The CR-POSSUM was first published in 2004. It com-
prises 10 variables, and the weights assigned to these
variables make it possible to calculate a physiologic com-
ponent and an intervention component, which in turn
make it possible to use logistic regression to estimate
the expected probability of death [5]. These models have
been validated in some developed countries; although
their overall discriminatory capacity is acceptable, they
tend to overestimate the risk of mortality in low risk pa-
tients [6]. In the recent years, other simpler models have
been developed in Europe: The model elaborated by the
Association Française de Chirurgie (AFC) to predict in-
hospital mortality in colorectal surgery consists of only
four variables [7], and the recently published and
externally validated Identification of Risk in Colorectal
Surgery (IRCS) score consists of five variables [8].
A good predictive model should be feasible (the
variables should be measurable before surgery), simple,
and able to discriminate or identify outcomes accurately.
To date, although some of these models have been
validated in the countries where they were devised or in
other developed countries, there is no consensus about
the most appropriate instrument for predicting the risk
of operative mortality. In Spain, surgery for colorectal
cancer is done both at smaller, local hospitals with
relatively small volumes of surgical interventions and at
larger, referral hospitals with large volumes of surgical
interventions. Although estimations of some quality and
outcome indicators for colorectal cancer surgery at a
local level have been published in Spain [9–11], and
although some departments of surgery in our setting
used the POSSUM models for clinical purposes until we
initiated this coordinated study in 2009, there had been
no validation of those models in our context and neither
no predictive model had been generally adopted by
surgeons to guide clinical decision making. Because the
variables in the CR-POSSUM and the other POSSUM
models include those variables that are considered in the
IRCS and the AFC models, we thought appropriate to
validate also the IRCS and AFC models in Spain.
Thus, we aimed to estimate the operative mortality in
surgery for colorectal cancer in Spain, to validate and
recalibrate the CR- POSSUM model in the Spanish
context, and to compare its discriminatory capacity with
that of other models developed in Europe to predict
operative mortality in surgery for colorectal cancer.
Methods
Design, setting, and patients
This prospective multicenter cohort study of patients
from 22 hospitals located in different areas in Spain was
done in the context of the REDISSEC (Health Services
Research on Chronic Diseases Network)/CCR-CARESS
(Colorectal Cancer Health Services Research) study,
which addressed diverse research objectives in health-
care centres treating colorectal cancer in Spain. All the
hospitals provided services for the National Health
System, and their size, location and level of technology
varied [12]. The Clinical Research Ethics Committees of
the Parc Taulí Sabadell-University Hospital; Hospital
del Mar; Fundació Unió Catalana d’Hospitals; Gipuzkoa
Health Area; Basque Country (CEIC-E); Hospital
Galdakao-Usansolo; Hospital Txagorritxu; Hospital
Basurto; La Paz University Hospital; Fundación Alcorcón
University Hospital; Hospital Universitario Clínico San
Carlos (formerly Clinical Research Ethics Committee of
Area 7 – Hospital Clínico San Carlos); Costa del Sol
Health Agency and the Regional Committee of Clinical
Trials of Andalusia approved the study, and all patients
provided written informed consent.
We included patients undergoing scheduled or urgent
surgery for primary invasive colorectal cancers in the
period comprising June 2010 through December 2012,
whether the goal of surgery was to excise the tumor or
to palliate symptoms.
The CCR-CARESS study, excluded patients considered
by the attending physician to be in very poor overall
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condition or have a very limited life expectancy; those
who declined to participate or did not sign the consent
form; those with only cancer in situ; those with relapsed
tumors; those with cancer not located in the colon or
rectum; those who died before the intervention; those
with inoperable cancer; those transferred for surgery in
another centre; and others (e.g., language problems).
Variables and data collection
Clinical data was gathered from clinical records or from
the surgeons of the team. The variables analyzed were a)
baseline characteristics such as age, sex, tumor location
(colon or rectum and the distance at the anal margin),
neurological comorbidities (dementia, cerebrovascular
disease, hemiplegia), weight loss > 10% in 6 months and,
clinical or pathological staging according to Dukes and
TNM [13]. b) preoperative variables such as laboratory
parameters (urea (mmol/l), haemoglobin (g/dL), leuco-
cytes (× 10^12/l), sodium (mmol/l), potassium (mmol/
l)), heart rate (beats/min), systolic blood pressure [SBP]
(mmHg), heart failure (none, mild, moderate, or severe),
signs of respiratory failure (no dyspnoea, dyspnoea on
exertion, limiting dyspnoea, dyspnoea at rest), electro-
cardiogram (normal, atrial fibrillation [AF], other abnor-
mal rhythm), and level of consciousness according to
the Glasgow Coma Score. c) surgical process variables
such as urgency of the intervention (scheduled, urgent,
or, when done < 2 h after presentation at the emergency
department, emergency), operative severity according to
the National Institute for Health and Care Excellence
[NICE] clinical guidelines (moderate, major or complex
major) [14], tumor resection (yes or no), number of
distinct surgical procedures in the same intervention
(including tumor excision, ostomy, or surgery on other
organs), peritoneal contamination (none, serous fluid,
local pus, free pus or faeces or blood), and total blood
loss (ml).
All patients were followed up after the intervention to
estimate two types of operative mortality: in-hospital
mortality, defined as death during the hospital stay,
regardless of the length of stay, and 30-day mortality,
defined as death within 30 days of the intervention,
whether occurring in the hospital or after discharge.
Models for predicting the risk of death
Table 1 lists the five models chosen to predict operative
mortality, and Additional file 1: Appendix A shows the
logistic regression formula used in each of them to
estimate the probability of death. All the models were
elaborated from some of the variables discussed above
plus an ‘intercept’. The POSSUM and P-POSSUM
models estimate a physiological score and an operative
severity score from 18 variables; each individual’s score
is calculated by summing his or her values for each
variable after weighting. Finally, each score is introduced
into the model and is then multiplied by its correspond-
ing β coefficient. The CR-POSSUM, the version specific
for colorectal surgery, includes only 10 variables, but the
formula for calculating the score is similar. The AFC
model does not involve a mathematical equation or any
weighting: it consists of 4 variables that are introduced
into a regression model [7]. The IRCS comprises 5 vari-
ables, each of which has a weight for each category and
is multiplied by the equation’s β coefficient [8].
Statistic analysis
Initially, we did a descriptive bivariate analysis of all the
variables in the models in relation with in-hospital
mortality and with 30-day mortality, using the chi-
square test or Fisher’s exact test for categorical variables.
We validated the 5 predictive models, using the
mathematical equations published by their creators
(Additional file 1: Appendix A) and calculating the risk
of operative mortality for each patient with the logistic
regression link function.
Then multivariate logistic regression techniques were
applied to recalibrate the 5 models, thus obtaining the
new β coefficients for each score (POSSUM, P-POSSUM
and CR-POSSUM models) or category of the variable
(IRCS and AFC models). For these purposes, patients
missing on any risk factor were excluded.
To calculate the discriminatory power of each model,
we used receiver operating characteristic curves, calcu-
lating the areas under the curve (AUC) and their 95%
confidence intervals. We considered an AUC between
70% and 80% moderate discrimination, between 80%
and 90% good discrimination, and greater than 90%
excellent [15]. We also estimated the calibration of the
models by applying the Hosmer-Lemeshow test. We
defined statistical significance as p < 0.05. We used IBM
SPSS Statistics 20 and R 2.15.3 for all analyses.
Results
A total of 3915 patients were recruited; 1166 (29.8%)
were excluded for the reasons shown in Fig. 1. Thus, we
analyzed 2749 patients (63.6% men; age range, 24–97 y;
mean age, 68 ± 11 y) operated on for primary invasive
colorectal cancer. The tumor was located in the colon in
1980 (72%) and in the rectum in 769 (28%) patients.
During hospital stay, 41 patients died (in-hospital op-
erative mortality, 1.5% [95% CI: 1.0–1.9]) and 47 patients
died within 30 days of the intervention (30-day operative
mortality, 1.7% [95% CI: 1.2–2.2]).
Table 2 shows the variables in the CR-POSSUM in re-
lation to in-hospital and 30-day mortality, as well as the
summary of the physiological and operative severity
scores. All the variables were significantly associated
with in-hospital mortality and 30-day mortality, except
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heart rate, urea, and cancer stage, although stage was as-
sociated with 30-day mortality. Mortality was especially
high in older patients, those with hypotension or heart
failure, those undergoing urgent surgery, and those with
free pus or faeces or blood. Additional file 1: Appendices
B and C show the analysis of the factors used in the
POSSUM, P-POSSUM, IRCS and AFC models. In the
validation analysis, the discriminatory power of the CR-
POSSUM for predicting in-hospital mortality was 73.6%,
and the discriminatory power of the other models was
similar (Table 3), although the number of patients with
complete data as well as the number of deaths included
in each model is different. When the models were
recalibrated, the AUCs improved slightly (see Additional
file 1: Appendix D and E for re-calibrated equations):
the CR-POSSUM reached 75.5% (95% CI: 67.3–83.7)
and the IRCS model had the highest discriminatory
power with an AUC of 76.2 (95% CI: 68.0–84.5). The
discriminatory power of the CR-POSSUM for predicting
30-day mortality was 74.2% (95% CI: 67.1–81.2) after re-
calibration; among the other recalibrated models the
POSSUM had the greatest discriminatory power, with an
AUC of 77.0% (95% CI: 68.9–85.2). Although the
Hosmer-Lemeshow test showed good fit for all the
recalibrated models, the original CR-POSSUM, as well
as the original versions of the other models tended to
overestimate the probability of operative death (Fig. 2).
Discussion
In surgery for colorectal cancer, in-hospital mortality
was 1.5% and 30-day mortality was 1.7%. The CR-
POSSUM model, like the other validated models, overes-
timated operative mortality; once recalibrated, it had
moderate discriminatory power as evidenced by the
75.5% AUC for in-hospital mortality and the 74.2% AUC
for 30-day mortality.
Operative mortality
The operative mortality observed in the present study is
near the lower limits of the range of the estimations re-
ported in similar studies [5, 16–26]. The 30-day mortal-
ity in these studies ranges from 0.7 and 11.3%. Various
factors might have contributed to our low mortality
rates. First, the proportion of patients undergoing urgent
surgery in our study was low. Given that operative mor-
tality is lower in scheduled than in urgent surgery, we
would expect lower mortality in our series than in series
with higher proportions of patients undergoing urgent
surgery. Nevertheless, it is noteworthy that the operative
mortality in the patients in our series that underwent ur-
gent surgery was also lower than that reported in other
previous studies. On the other hand, the patients in our
study were operated on for a primary tumor in the
period comprising 2010 through 2012, whereas most of
the other studies discussed here examined earlier pe-
riods; thus, we cannot rule out a period effect involving
a secular decrease in operative mortality for this kind of
surgery over time due to various factors (e.g., improve-
ments in perioperative management or different selec-
tion criteria for indication of surgery).
Validity of CR-POSSUM and other POSSUM models
This validation and recalibration study of models for
predicting operative mortality in a widespread, sample of
Spanish hospitals found that the CR-POSSUM, has
moderate discriminatory power, similar to that found in
the external validation studies [8, 18, 25]. However, the
Table 1 Review of scoring systems validated
Model Year of publication Country of
development
Population Number of model
parameters
Validation AUC [range]
(Number of studies)
POSSUM 1991 United Kingdom General surgery 18 External [62.7–81.0] (10)
P-POSSUM 1996 United Kingdom General surgery 18 External [64.8–86.8] (13)
CR-POSSUM 2004 United Kingdom Colorectal surgery 10 External [59.0–89.8] (22)
AFC 2005 France Colorectal surgery for malignant
or diverticular disease
4 External [71.4–89.0] (6)
IRCS 2014 Netherlands, Spain Colorectal surgery 5 External [83.0–85.0] (2)
AUC Area under the curve
Fig. 1 Sample size and exclusion criteria
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Table 2 Univariate and Bivariate analysis of CR-POSSUM factors for operative mortality
Total (N = 2749) In-hospital mortality (N = 41) 30-day mortality (N = 47)
Weight N % Col N % Row p-value N % Row p-value
Age 1 <=60 640 23.3 2 0.3 < 0.001 2 0.3 < 0.001
3 61–70 830 30.2 7 0.8 10 1.2
4 71–80 902 32.9 14 1.6 16 1.8
8 > = 81 373 13.6 18 4.8 19 5.1
missing 4 0.1
Heart failure 1 None or mild 2487 92.9 31 1.2 < 0.001 36 1.4 < 0.001
2 Moderate 144 5.4 6 4.2 7 4.9
3 Severe 45 1.7 3 6.7 3 6.7
missing 73 2.7
Systolic blood pressure (mmHg) 1 100–170 2452 93.1 34 1.4 0.004 39 1.6 0.007
2 > 170 or 90–99 161 6.1 4 2.5 5 3.1
3 < 90 20 0.8 2 10.0 2 10.0
missing 116 4.2
Heart rate (beats/min) 1 40–100 2516 96.6 36 1.4 0.186 42 1.7 0.289
2 101–120 76 2.9 3 3.9 3 3.9
3 > 120 or < 40 13 0.5 0 0.0 0 0.0
missing 144 5.2
Urea (mmol/l) 1 <=10.0 767 31.1 14 1.8 0.440 15 2.0 0.363
2 10.1–15.0 1005 40.8 12 1.2 15 1.5
3 > 15.0 694 28.1 13 1.9 17 2.4
missing 283 10.3
Haemoglobin (g/dl) 1 13.0–16.0 1053 39.1 13 1.2 0.023 12 1.1 0.002
2 10.0–12.9 or 16.1–18.0 1290 47.9 16 1.2 21 1.6
3 < 10.0 or > 18.0 350 13.0 11 3.1 14 4.0
missing 56 2.0
Physiological score:
in-hospital mortality
mean: std. dev: median: min: max: missing:
No 10.4 2.6 10.0 6.0 19.0 453
Yes 12.9 2.9 13.0 6.0 19.0 3
Operative severity 1 Minor 0 0.0 0 0.0 0.003 0 0.0 < 0.001
3 Moderate 60 2.2 4 6.7 5 8.3
4 Major 1520 55.4 19 1.3 21 1.4
8 Complex major 1164 42.4 18 1.5 21 1.8
missing 5 0.2
Peritoneal contamination 1 None or serous fluid 2683 98.0 37 1.4 0.001 42 1.6 < 0.001
2 Local pus 9 0.3 1 11.1 1 11.1
3 Free pus or faeces
or blood
46 1.7 3 6.5 4 8.7
missing 11 0.4
Operative urgency 1 Scheduled 2649 96.4 34 1.3 < 0.001 38 1.4 < 0.001
3 Urgent 93 3.4 6 6.5 8 8.6
8 Emergency 7 0.3 1 14.3 1 14.3
missing 0 0.0
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original versions of this and the other models overesti-
mated the operative mortality. To a certain extent, the low
mortality observed in our cohort and the number of vari-
ables in the model limits our capacity to identify signifi-
cant associations. It is worth mentioning that the model
was designed to estimate in-hospital mortality, but we
have seen that the AUC is similar for both types of mortal-
ity measure. On the other hand, this model was not
designed solely for patients with colorectal cancer. One of
the most widely questioned aspects of this model and of
its predecessors, the POSSUM and P-POSSUM, is that
some of the variables (operative variables) are not available
until after the intervention; thus, they are not useful for
predicting operative death. Another questionable aspect
refers to the difficulties involved in obtaining all of the
required variables (e.g., urea, staging), as we have observed
in our study, despite its prospective design. For this rea-
son, the other POSSUM models have similar limitations
because they require collecting an even larger number of
variables than the CR-POSSUM without resulting in
appreciable improvements in their predictive capacity. In
the bivariate analysis, some of the variables were not
significantly associated with either in-hospital or 30-day
mortality. Nevertheless, the discriminatory capacity of the
three models was similar, considering their AUC and con-
fidence intervals. In 2010, Richards et al. [27] reviewed the
validation studies of these models, concluding that the
P-POSSUM had the greatest discriminatory power of the
three for colorectal cancer and that the CR-POSSUM,
with an AUC < 75%, did not add any value, although a
more recent external validation study reported better
results [28]. It is therefore not surprising that several
research teams have attempted to develop better models,
given the contradictory results published before [29].
Comparison with other models and with the literature
Of the models developed in Europe, the recently created
IRCS model, which has fewer variables, yields a discrim-
inatory capacity similar or even better than the POS-
SUM models; in our study, the IRCS predicted the
outcome correctly in about three-quarters of the patients.
In fact, of the models evaluated in this study, the IRCS is
the one that best discriminated in-hospital operative
mortality, although the POSSUM was slightly better at
discriminating 30-day operative mortality. This difference
might be related to the fact that advanced disease might
not have as strong an impact on more immediate mortal-
ity as on longer-term mortality. Another advantage of the
IRCS is the low number of variables, all of which, more-
over, can be measured before the intervention, increasing
the usefulness of the model for identifying patients at risk.
None of the models used is specific for colorectal cancer;
however, it might be that the more specific a model is for
a particular disease or subgroup of patients (e.g., the
elderly), the more complex its construction is, the lower
its external validity, and the more difficult it will be to
extend its use for clinical purposes or for assessment. This
could explain why many of the models described in the
literature have not had a great impact on clinical practice.
Very recently, a new model to predict in-hospital
mortality in patients undergoing colorectal surgery, the
Colorectal preOperative Surgical Score (CrOSS), was
created and externally validated in Australia. Although it
needs to be validated in other contexts, this model
achieved an AUC of 0.87. It has the great advantage of
considering only four variables, all of which can be
assessed preoperatively (age, urgency of the intervention,
albumin, and heart failure) [30]. The Association of
Coloproctology of Great Britain and Ireland used multi-
level analysis to devise a model specifically for predicting
mortality risk in surgery for colorectal cancer, the
ACPGBI-CRC. This model achieved an AUC of 77%
[17]. Using one of the largest series of patients operated
on for colorectal cancer, Walker et al. [24] devised a
model that yielded an AUC of about 80% for estimating
90-day mortality. In this model, the predictor with the
strongest association was the American Society of Anes-
thesiologists Physical Status classification (ASA grade),
which itself has certain limitations in predicting surgical
risk [31]. As for other predictive factors, advanced age is
consistently associated with higher risk of death in the
various models developed, as it is in many other health
Table 2 Univariate and Bivariate analysis of CR-POSSUM factors for operative mortality (Continued)
Total (N = 2749) In-hospital mortality (N = 41) 30-day mortality (N = 47)
Weight N % Col N % Row p-value N % Row p-value
Clinical or pathological
cancer staging
1 Dukes’ A-B 1582 57.9 20 1.3 0.484 21 1.3 0.003
2 Dukes’ C 895 32.7 16 1.8 15 1.7
3 Dukes’ D 256 9.4 5 2.0 11 4.3
missing 16 0.6
Operative severity score:
in-hospital mortality
mean: std. dev: median: min: max: missing:
No 9.3 2.2 8.0 6.0 20.0 453
Yes 10.0 2.5 11.0 6.0 16.0 3
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problems. Likewise, the urgency of the intervention, which
reflects the patient’s condition, and certain underlying
heart conditions are present in many of the models.
Albumin or weight loss > 10% in the 6 months preceding
surgery, both of which are indirect indicators of malnutri-
tion before the intervention, also appear in different
models. In fact, malnutrition is a clear risk factor for worse
postoperative outcome in general, especially in older
patients; it might also be the only factor considered in the
models that can be modified before scheduled surgery.
The introduction of laparoscopic surgery in recent
decades changes the scenario, and it is important to
consider to what extent the lower risk of death reported
in some studies [32] is independent of other factors.
One of the most illustrative clinical trials found no dif-
ferences in mortality between laparoscopic surgery and
conventional open surgery [33]. In fact, most variables in
the models are more related to the patient’s clinical con-
dition than to the surgical technique used.
Limitations
The cohort in this study includes a large series of
patients recruited at 22 hospitals. As in all observational
studies, the absence of information can be a limitation,
although the prospective design and the quality control
have enabled us to ensure thorough data collection. The
missing data for some variables (e.g., some laboratory
parameters) is due mostly to the unavailability of these
factors in clinical practice, especially in the most urgent
interventions. This made it impossible for us to use the
entire sample of patients for some models; however,
rather than a limitation due to the study design, this
limitation is due to the models’ incompatibility with the
available clinical information and/or routine clinical
practice in our context. On the other hand, the mortality
rate was low, with fewer than 50 deaths in both
mortality indicators, and this might have compromised
our capacity for recalibrating the models; however, in
part thanks to the low mortality in our series, we were
able to see that the original models considerably overes-
timated the risk of death.
Clinical implications
This is the first multicenter study in Spain to validate and
recalibrate some of the models for predicting operative
mortality in a large cohort of patients operated on for
colorectal cancer. Our data show that the operative mor-
tality in these patients was low and that the models based
on few variables that can be obtained in patients undergo-
ing urgent surgery as well as those undergoing scheduled
surgery can be useful in our healthcare system. Of the
models we evaluated, the IRCS, which takes into account
the patient’s age, the urgency of the intervention, the stage
of disease, and the presence of respiratory failure or heart
failure, is the one that might have the greatest discrimin-
atory power for in-hospital mortality, although the POS-
SUM might be slightly better for predicting 30-day
mortality. Nevertheless, there is considerable disparity in
the factors that make up the models and none of them are
generally used throughout Europe or in other areas,
perhaps due to their moderate capacity to discriminate in
the different contexts where they have been externally
validated, as in our study. Our findings underline the need
for a model that has better capacity to discriminate
patients at greater risk; such a model should have face
validity, be easy to apply, and be based on factors that can
be measured before the intervention.
Conclusions
The CR-POSSUM and the other models analyzed in this
study showed moderate capability to discriminate the
risk of operative mortality in our context, where the
Fig. 2 Operative death estimated by POSSUM, P-POSSUM, CR-POSSUM and IRCS
Baré et al. BMC Health Services Research  (2018) 18:49 Page 8 of 10
actual operative mortality is low. The IRCS model
yielded similar results with fewer variables, all of which
are available before the intervention. To optimize pre-
operative management and reduce operative mortality in
patients undergoing surgery for colorectal cancer as far
as possible, we need a model that can better discriminate
the patients with greater risk.
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